Kvartalsrapport Q2 2026

===== SIDA 1 =====

PRESS RELEASE
04 August 2026 10:00:00 CEST
    Cantargia AB Scheelevägen 27 SE-223 63 Lund• •
Cantargia to host Q2 2026 Interim Results 
Conference Call
Cantargia AB (publ), “Cantargia” (Nasdaq Stockholm: CANTA) will publish its 
interim report for January – June 2026 on Wednesday, August 19, 2026, at 07:00 a.
m. CEST.
Interested investors, analysts, and media are invited to Cantargia’s quarterly conference call on 
the same date at 3:00 p.m. CEST. The event will be hosted by Cantargia’s CEO Hilde Steineger 
and CFO Patrik Renblad. During the call, management will review the Company’s interim 
financial results and provide a business and pipeline update. The presentation will be held in 
English.
If you wish to participate via audiocast, please use the link below. Via the web session you will be 
able to ask written questions. Webcast: .https://cantargia.events.inderes.com/q2-report-2026
If you wish to participate via teleconference, please register on the link below. After registration 
you will be provided with phone numbers and a conference ID to access the conference. You can 
ask questions verbally via the teleconference.
.https://events.inderes.com/cantargia/q2-report-2026/dial-in
The webcast and the presentation will also be available on demand on Cantargia’s corporate 
website: www.cantargia.com
For further information, please contact
Hilde Steineger, CEO
Telephone: +46 (0)46-275 62 60
E-mail: info@cantargia.com
About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-
based treatments for life-threatening diseases and has established a platform based on the 
protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia’s 
oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in 
combination with chemotherapy with a focus on pancreatic cancer and non-small cell lung 
cancer. Positive data for the combinations indicate stronger efficacy than would be expected from 
chemotherapy alone. Cantargia’s second development program, the antibody CAN10, blocks 
signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious 
autoimmune/inflammatory diseases. In September 2025, the acquisition of CAN10 by Otsuka 
Pharmaceutical was completed.
 
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is 
available at .www.cantargia.com

===== SIDA 2 =====

PRESS RELEASE
04 August 2026 10:00:00 CEST
    Cantargia AB Scheelevägen 27 SE-223 63 Lund• •
Attachments
Cantargia to host Q2 2026 Interim Results Conference Call